OBJECTIVE: Systemic lupus erythematosus (SLE) and lupus nephritis (LN) disproportionately affect individuals who are members of racial/ethnic minority groups and individuals of lower socioeconomic status (SES). This study was undertaken to investigate the epidemiology and sociodemographics of SLE and LN in the low-income US Medicaid population. METHODS: We utilized Medicaid Analytic eXtract data, with billing claims from 47 states and Washington, DC, for 23.9 million individuals ages 18-65 years who were enrolled in Medicaid for >3 months in 2000-2004. Individuals with SLE (≥3 visits >30 days apart with an International Classification of Diseases, Ninth Revision [ICD-9] code of 710.0) and with LN (≥2 visits with an ICD-9 code for glomerulonephritis, proteinuria, or renal failure) were identified. We calculated SLE and LN prevalence and incidence, stratified by sociodemographic category, and adjusted for number of American College of Rheumatology (ACR) member rheumatologists in the state and SES using a validated composite of US Census variables. RESULTS: We identified 34,339 individuals with SLE (prevalence 143.7 per 100,000) and 7,388 (21.5%) with LN (prevalence 30.9 per 100,000). SLE prevalence was 6 times higher among women, nearly double in African American compared to white women, and highest in the US South. LN prevalence was higher among all racial/ethnic minority groups compared to whites. The areas with lowest SES had the highest prevalence; areas with the fewest ACR rheumatologists had the lowest prevalence. SLE incidence was 23.2 per 100,000 person-years and LN incidence was 6.9 per 100,000 person-years, with similar sociodemographic trends. CONCLUSION: In this nationwide Medicaid population, there was sociodemographic variation in SLE and LN prevalence and incidence. Understanding the increased burden of SLE and its complications in this low-income population has implications for resource allocation and access to subspecialty care.
OBJECTIVE:Systemic lupus erythematosus (SLE) and lupus nephritis (LN) disproportionately affect individuals who are members of racial/ethnic minority groups and individuals of lower socioeconomic status (SES). This study was undertaken to investigate the epidemiology and sociodemographics of SLE and LN in the low-income US Medicaid population. METHODS: We utilized Medicaid Analytic eXtract data, with billing claims from 47 states and Washington, DC, for 23.9 million individuals ages 18-65 years who were enrolled in Medicaid for >3 months in 2000-2004. Individuals with SLE (≥3 visits >30 days apart with an International Classification of Diseases, Ninth Revision [ICD-9] code of 710.0) and with LN (≥2 visits with an ICD-9 code for glomerulonephritis, proteinuria, or renal failure) were identified. We calculated SLE and LN prevalence and incidence, stratified by sociodemographic category, and adjusted for number of American College of Rheumatology (ACR) member rheumatologists in the state and SES using a validated composite of US Census variables. RESULTS: We identified 34,339 individuals with SLE (prevalence 143.7 per 100,000) and 7,388 (21.5%) with LN (prevalence 30.9 per 100,000). SLE prevalence was 6 times higher among women, nearly double in African American compared to white women, and highest in the US South. LN prevalence was higher among all racial/ethnic minority groups compared to whites. The areas with lowest SES had the highest prevalence; areas with the fewest ACR rheumatologists had the lowest prevalence. SLE incidence was 23.2 per 100,000 person-years and LN incidence was 6.9 per 100,000 person-years, with similar sociodemographic trends. CONCLUSION: In this nationwide Medicaid population, there was sociodemographic variation in SLE and LN prevalence and incidence. Understanding the increased burden of SLE and its complications in this low-income population has implications for resource allocation and access to subspecialty care.
Authors: Daniel H Solomon; John Z Ayanian; Ed Yelin; Tamara Shaykevich; M Alan Brookhart; Jeffrey N Katz Journal: Arthritis Care Res (Hoboken) Date: 2012-02 Impact factor: 4.794
Authors: H M Bastian; J M Roseman; G McGwin; G S Alarcón; A W Friedman; B J Fessler; B A Baethge; J D Reveille Journal: Lupus Date: 2002 Impact factor: 2.911
Authors: Ana V Diez Roux; Luisa N Borrell; Mary Haan; Sharon A Jackson; Richard Schultz Journal: J Epidemiol Community Health Date: 2004-11 Impact factor: 3.710
Authors: M Cristina Kenney; Marilyn Chwa; Shari R Atilano; Payam Falatoonzadeh; Claudio Ramirez; Deepika Malik; Mohamed Tarek; Javier Cáceres Del Carpio; Anthony B Nesburn; David S Boyer; Baruch D Kuppermann; Marquis P Vawter; S Michal Jazwinski; Michael V Miceli; Douglas C Wallace; Nitin Udar Journal: Biochim Biophys Acta Date: 2013-11-04
Authors: Linda T Hiraki; Candace H Feldman; Francisco M Marty; Wolfgang C Winkelmayer; Hongshu Guan; Karen H Costenbader Journal: Arthritis Care Res (Hoboken) Date: 2017-09-21 Impact factor: 4.794
Authors: Tzu-Chieh Lin; Michael F Marmor; Medha Barbhaiya; Hongshu Guan; Sarah K Chen; Candace H Feldman; Karen H Costenbader Journal: Arthritis Care Res (Hoboken) Date: 2018-11 Impact factor: 4.794
Authors: Jinoos Yazdany; Candace H Feldman; Jun Liu; Michael M Ward; Michael A Fischer; Karen H Costenbader Journal: Arthritis Care Res (Hoboken) Date: 2014-04 Impact factor: 4.794
Authors: Candace H Feldman; LeRoi S Hicks; Tabatha L Norton; Elmer Freeman; Daniel H Solomon Journal: J Clin Rheumatol Date: 2013-10 Impact factor: 3.517